1. Home
  2. GANX vs ADVM Comparison

GANX vs ADVM Comparison

Compare GANX & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • ADVM
  • Stock Information
  • Founded
  • GANX 2017
  • ADVM 2006
  • Country
  • GANX United States
  • ADVM United States
  • Employees
  • GANX N/A
  • ADVM N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GANX Health Care
  • ADVM Health Care
  • Exchange
  • GANX Nasdaq
  • ADVM Nasdaq
  • Market Cap
  • GANX 53.4M
  • ADVM 59.6M
  • IPO Year
  • GANX 2021
  • ADVM 2014
  • Fundamental
  • Price
  • GANX $1.92
  • ADVM $3.16
  • Analyst Decision
  • GANX Strong Buy
  • ADVM Strong Buy
  • Analyst Count
  • GANX 5
  • ADVM 4
  • Target Price
  • GANX $8.00
  • ADVM $19.75
  • AVG Volume (30 Days)
  • GANX 378.4K
  • ADVM 96.4K
  • Earning Date
  • GANX 08-12-2025
  • ADVM 08-12-2025
  • Dividend Yield
  • GANX N/A
  • ADVM N/A
  • EPS Growth
  • GANX N/A
  • ADVM N/A
  • EPS
  • GANX N/A
  • ADVM N/A
  • Revenue
  • GANX N/A
  • ADVM $1,000,000.00
  • Revenue This Year
  • GANX N/A
  • ADVM $1,836.70
  • Revenue Next Year
  • GANX N/A
  • ADVM N/A
  • P/E Ratio
  • GANX N/A
  • ADVM N/A
  • Revenue Growth
  • GANX N/A
  • ADVM N/A
  • 52 Week Low
  • GANX $0.95
  • ADVM $1.78
  • 52 Week High
  • GANX $3.19
  • ADVM $8.56
  • Technical
  • Relative Strength Index (RSI)
  • GANX 61.71
  • ADVM 67.91
  • Support Level
  • GANX $1.65
  • ADVM $2.20
  • Resistance Level
  • GANX $2.07
  • ADVM $3.25
  • Average True Range (ATR)
  • GANX 0.16
  • ADVM 0.22
  • MACD
  • GANX 0.05
  • ADVM 0.06
  • Stochastic Oscillator
  • GANX 70.15
  • ADVM 91.43

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Share on Social Networks: